HOME >> BIOLOGY >> NEWS
Malaria: The right vaccine in the right place?

A new study by Christopher Plowe and colleagues (University of Maryland School of Medicine) on a malaria vaccine used at a testing site in Mali calls into question whether the best vaccine was chosen to be tested at this particular site.

The development of an effective malaria vaccine is not easy, in part because there are different strains of the Plasmodium parasite that causes the disease. The different strains carry different variants (alleles) of the genes encoding parasite components (antigens) used in test vaccines, which means that the parasites causing infection in a given location may differ from the ones used for vaccination. If this is the case, the immune response generated by the vaccine might be less effective or even ineffective.

Plowe and colleagues investigated an antigen called MSP-119, which is included in a candidate vaccine that was recently tested in Mali. The MSP-119 gene contains six polymorphisms (variations) that can occur in various combinations (haplotypes); the candidate vaccine contained MSP-119 from the 3D7 strain of P. falciparum.

The researchers used DNA sequencing to examine the MSP-119 gene in more than 1300 malaria infections in 100 Malian children. They compared the frequencies of 14 different MSP-119 haplotypes over three years, in three age groups, and in consecutive infections within individuals. They found that the frequency of individual MSP-119 haplotypes fluctuated in their study population, but that the P. falciparum 3D7 MSP-119 haplotype was present in only 16% of the infections. (In contrast, combinations found in P. falciparum FVO and FUP strains were each present in about 40% of the infections.)

These findings show that most parasites at the Malian vaccine test site make a different form of MSP-119 than the one contained in the vaccine. Although early results from field trials suggest that the 3D7-derived vaccine may provide some protection against the more common FVO and
'"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
12-Mar-2007


Page: 1 2

Related biology news :

1. Malaria: Efficacy of monotherapies in Cameroon
2. When off-target is right on
3. Study identifies energy efficiency as reason for evolution of upright walking
4. Brightly colored birds most affected by Chernobyl radiation
5. Bright future for nano-sized light source
6. Wright State scientist receives grant to help clean up polluted American harbors
7. Human ancestors learned to walk upright in the trees, say experts
8. Lessons from the orangutans: Upright walking may have begun in the trees
9. Left-right wiring determined by neural communication in the embryonic worm
10. Genes and biomarkers that allow doctors to choose the right therapy for the right patient
11. Traveling in the right direction -- lessening our impact on the environment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2019)... , ... April 24, 2019 , ... ... announces today the award of U.S. patent 10,191,929, “Systems and Methods for SNP ... and more efficient to conduct a variety of advanced bioinformatic analyses, including SNP ...
(Date:4/18/2019)... and WALNUT CREEK, Calif. (PRWEB) , ... April ... ... management solution for the healthcare industry, today announced the launch of mSource® AI ... processing to extract deep knowledge of Medpricer customers’ supplier contracts, truly optimizing purchased ...
(Date:4/16/2019)... ... April 16, 2019 , ... HealthLink International, experts ... its new medical device facility on Friday, April 12. Headquartered in the Netherlands, ... new facility includes 108,500 square feet and houses 32 employees enabling HealthLink to ...
Breaking Biology News(10 mins):
(Date:4/25/2019)... , ... April 24, 2019 , ... ... Agents for sales and service organizations, today announced global availability of Inference ... providers and enterprises of all sizes to harness the power of Google’s ...
(Date:4/15/2019)... ... April 15, 2019 , ... ... of a $2 million bench plant expansion to increase production of methylene malonate ... the design and construction of Sirrus’ full-scale production facility, which is scheduled to ...
(Date:4/9/2019)... , ... April 09, 2019 , ... ... focused on increasing the capacity of life sciences organizations to accelerate innovation and ... Assurance platform in the past 12 months. , USDM’s Cloud Assurance ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global ... $15 million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). ... Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready to begin ...
Breaking Biology Technology:
Cached News: